Figure - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Comparisons of patient's general assessment of snoring reduction variables before and after laser treatment.
Source publication
Background: Surgical treatments for snoring and sleep-related symptoms are invasive, may have complications, have inconstant success rates, and may have a significant relapse rate. Methods: We evaluated the effectiveness of a non-surgical, non-invasive outpatient 808 nm diode laser treatment. Forty-five patients with snoring and sleep disorders wer...
Contexts in source publication
Citations
... The panel reviewed 2 meta-analyses 112,113 and several studies addressing NALT in treating adult OSA or snoring. [114][115][116][117][118][119][120][121][122][123][124] The majority of the studies used Er:YAG 2940-nm laser stimulation. The successful outcomes reported in one of the review articles 113 confounded ablative and nonablative studies as well as animal studies and, therefore, overstated the limited evidence to support NALT. ...
... Parameters measuring significant improvement in AHI or the respiratory disturbance index were limited to 2 studies, one of which had significant design flaws rendering the outcomes questionable 119 and the other using proprietary diode 810nm laser settings that are not shared by the laser manufacturer. 124 Other study outcomes included static soft palate length using Mallampati scores, airway volume and minimal cross-sectional area by cone-beam computed tomography in awake nonsupine study participants, ESS, snoring using subjective measures or a smartphone app, treatment satisfaction, and untoward adverse effects. While such outcomes are commonly assessed in such studies, they are not currently recognized as valid measures to judge treatment success. ...
... In vitro evidence has shown PBM therapy irradiated with the FT-HP is more effective, predictable, and repeatable than with standard probes [24,25]. Through the use of the FT-HP, a therapy, consisting of 808 nm of wavelength and 1 W of power irradiated for 60 s in continuous-wave (CW) on a spot-size area of 1 cm 2 to generate a fluence of 60 J/cm 2 and a power density of 1 W/cm 2 , was selected and characterized on isolated mitochondrial [19,20,23,25], cellular [26,27], and animal models [28,29], as well as on humans [30,31]. ...
... The use of intranasal influenza vaccines was also excluded. isolated mitochondrial [19,20,23,25], cellular [26,27], and animal models [28,29], as well as on humans [30,31]. Therefore, according to our previous works [25,30], we hypothesize that 808 nm 1 W, 1 W/cm 2 , and 60 J/cm 2 laser therapy, irradiated through the FT-HP, could support the recovery of patients affected by BP. ...
Diminished facial movement and marked facial asymmetry can lead to a consistent psychological burden. Bell′s palsy (BP) is one of the most common causes of facial nerve illness, which comes with unilateral acute facial paresis. Nowadays, no clear guidelines for treating BP are available. We carried out a case series study to test the efficacy of photobiomodulation (PBM) therapy in patients with BP non-responsive to standard treatment. The study was experimentally performed at the Department of Surgical and Diagnostic Sciences, University of Genoa (Genoa, Italy), in accordance with case report guidelines. Patients were referred to our department by colleagues for evaluation to be included in the case series because no consistent improvement was observed at least 3 months from the diagnosis of BP. All the patients interrupted their pharmacological therapy before the initiation of PBM therapy. PBM therapy (808 nm, 1 W irradiated in continuous-wave for 60 s on spot-size 1 cm2; 1 W/cm2; 60 J/cm2; and 60 J) was administered every 2 days until complete resolution. Evaluation of the House-Brackmann scale was performed before and after treatments. Fourteen patients were screened as eligible for the study. Patients were Caucasians (36% females and 64% males) with a mean age ± standard deviation of 56.07 ± 15.21 years. Eleven patients out of 14, who experienced BP a maximum of 6 months, completely recovered through PBM. The three patients that did not show improvement were those who had experienced BP for years. PBM could be a supportive therapy for the management of BP in patients non-responsive to standard treatment. However, randomized controlled trials are necessary to sustain our encouraging results, exclude bias, and better explain the boundary between the time from diagnosis and the recovery of BP through PBM therapy.
